中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
Chinese Journal of Biochemical Pharmaceutics
2015年
10期
172-177,182
,共7页
莫西沙星%急性盆腔炎%中国%Meta分析
莫西沙星%急性盆腔炎%中國%Meta分析
막서사성%급성분강염%중국%Meta분석
moxifloxacin%acute pelvic inflammatory disease%Meta analysis
目的 应用Meta分析法分析评价莫西沙星治疗急性盆腔炎的疗效和安全性.方法 在Pubmed、MEDLINE、Cochrane图书馆、中国生物医学文献数据库、中国学术期刊网全文数据库(CNKI)和中国万方医学数据库和维普数据库中检索2000年1月~2014年12月国内外公开发表的关于中国地区应用莫西沙星治疗急性盆腔炎的临床随机对照试验文献,浏览全文并从中筛选符合纳入标准的试验进行研究,提取数据后,采用Review Manager 5.1.7软件统计并分析相关数据.结果 共有14项研究符合纳入标准.相对于对照组,莫西沙星治疗急性盆腔炎的临床疗效比值比(odds ratio,OR)合并值为3.76[95%置信区间(CI)2.14-6.59,P<0.01].5项研究给出了具体的细菌清除率的数据,其合并效应量OR为2.34(95%CI 1.46-3.75,P<0.01).12项研究给出了不良反应的数据,其合并效应量OR为0.50(95%CI 0.30-0.86,P=0.01).结论 Meta分析结果显示,莫西沙星治疗急性盆腔炎安全、有效.但迄今我国应用莫西沙星治疗急性盆腔炎的研究相对较少,且研究质量的总体水平还有待提高.
目的 應用Meta分析法分析評價莫西沙星治療急性盆腔炎的療效和安全性.方法 在Pubmed、MEDLINE、Cochrane圖書館、中國生物醫學文獻數據庫、中國學術期刊網全文數據庫(CNKI)和中國萬方醫學數據庫和維普數據庫中檢索2000年1月~2014年12月國內外公開髮錶的關于中國地區應用莫西沙星治療急性盆腔炎的臨床隨機對照試驗文獻,瀏覽全文併從中篩選符閤納入標準的試驗進行研究,提取數據後,採用Review Manager 5.1.7軟件統計併分析相關數據.結果 共有14項研究符閤納入標準.相對于對照組,莫西沙星治療急性盆腔炎的臨床療效比值比(odds ratio,OR)閤併值為3.76[95%置信區間(CI)2.14-6.59,P<0.01].5項研究給齣瞭具體的細菌清除率的數據,其閤併效應量OR為2.34(95%CI 1.46-3.75,P<0.01).12項研究給齣瞭不良反應的數據,其閤併效應量OR為0.50(95%CI 0.30-0.86,P=0.01).結論 Meta分析結果顯示,莫西沙星治療急性盆腔炎安全、有效.但迄今我國應用莫西沙星治療急性盆腔炎的研究相對較少,且研究質量的總體水平還有待提高.
목적 응용Meta분석법분석평개막서사성치료급성분강염적료효화안전성.방법 재Pubmed、MEDLINE、Cochrane도서관、중국생물의학문헌수거고、중국학술기간망전문수거고(CNKI)화중국만방의학수거고화유보수거고중검색2000년1월~2014년12월국내외공개발표적관우중국지구응용막서사성치료급성분강염적림상수궤대조시험문헌,류람전문병종중사선부합납입표준적시험진행연구,제취수거후,채용Review Manager 5.1.7연건통계병분석상관수거.결과 공유14항연구부합납입표준.상대우대조조,막서사성치료급성분강염적림상료효비치비(odds ratio,OR)합병치위3.76[95%치신구간(CI)2.14-6.59,P<0.01].5항연구급출료구체적세균청제솔적수거,기합병효응량OR위2.34(95%CI 1.46-3.75,P<0.01).12항연구급출료불량반응적수거,기합병효응량OR위0.50(95%CI 0.30-0.86,P=0.01).결론 Meta분석결과현시,막서사성치료급성분강염안전、유효.단흘금아국응용막서사성치료급성분강염적연구상대교소,차연구질량적총체수평환유대제고.
Objective To evaluate curative effect and safety of moxifloxacin in treatment of acute pelvic inflammatory with Meta analysis.Methods The database of Pubmed, MEDLINE, Cochrane, China Biology Medicine disc (DBMdisc), China National Knowledge Infrastructure (CNKI), Wanfang med online and VIP were retrieved, and randomized clinical trials of moxifloxacin in treatment of acute pelvic inflammatory which were open literatures published at home and abroad were collected from January 2000 to December 2014.The literatures which were accorded with the criterion were chosen and analyzed by Review Manager 5.1.7.Results The results showed that there were 14 literatures which were homogenous corresponded with the criterion, changeless benefit model statistics and analysis showed that the odds ratio (OR) was 3.76(95%CI 2.14-6.59, P<0.01).And there were 5 studies on bacterial removal showed that the OR was 2.34(95%CI 1.46-3.75, P<0.01).There were 12 studies on incidence of adverse reactions showed that the OR was 0.5(95%CI 0.30-0.86,P=0.01).Conclusion Meta analysis displayed that moxifloxacin is effective for acute pelvic inflammatory.But the high quality RCTs were too few in domestic studies in treatment of the acute pelvic inflammation with moxifloxacin and the overall level of studied quality needs improvement urgently.
